{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:57:27Z","timestamp":1791615447289,"version":"4.3.4"},"reference-count":71,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005643","name":"University of Lodz","doi-asserted-by":"crossref","award":["506\/1136"],"award-info":[{"award-number":["506\/1136"]}],"id":[{"id":"10.13039\/501100005643","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004681","name":"Higher Education Commission, Pakistan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK9) is one of the key targets for atherosclerosis drug development as its binding with low-density lipoprotein receptor leads to atherosclerosis. The protein-ligand interaction helps to understand the actual mechanism for the pharmacological action. This research aims to discover the best inhibitory candidates targeting PCSK9. To start with, reported ACE inhibitors were incorporated into pharmacophore designing using PharmaGist to produce pharmacophore models. Selected models were later screened against the ZINC database using ZINCPHARMER to define potential drug candidates that were docked with the target protein to understand their interactions. Molecular docking revealed the top 10 drug candidates against PCSK9, with binding energies ranging from -9.8 kcal\u00b7mol<jats:sup>-1<\/jats:sup>to -8.2 kcal\u00b7mol<jats:sup>-1<\/jats:sup>, which were analyzed for their pharmacokinetic properties and oral bioavailability. Some compounds were identified as plant-derived compounds like (S)-canadine, hesperetin or labetalol (an antihypertensive drug). Molecular dynamics results showed that these substances formed stable protein-ligand complexes. (S)-canadine-PCSK9 complex was the most stable with the lowest RMSD. It was concluded that (S)-canadine may act as a potential inhibitor against atherosclerosis for the development of new PCSK9 inhibitory drugs in future<jats:italic>in vitro<\/jats:italic>research.<\/jats:p>","DOI":"10.1371\/journal.pone.0255523","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T17:36:48Z","timestamp":1628185008000},"page":"e0255523","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Finding inhibitors for PCSK9 using computational methods"],"prefix":"10.1371","volume":"16","author":[{"given":"Rida","family":"Zainab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3972-0051","authenticated-orcid":true,"given":"Afshan","family":"Kaleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0839-8004","authenticated-orcid":true,"given":"Micha\u0142 B.","family":"Ponczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3932-6297","authenticated-orcid":true,"given":"Roheena","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehwish","family":"Iqtedar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4903-9235","authenticated-orcid":true,"given":"Daniel C.","family":"Hoessli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"pone.0255523.ref001","first-page":"225","article-title":"Genetic determinants of myocardial infarction risk in familial hypercholesterolemia","volume":"1","author":"PJ Zhao","year":"2019","journal-title":"Can J Cardiol"},{"key":"pone.0255523.ref002","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"AV Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"pone.0255523.ref003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/jcdd7020016","article-title":"Verification of Underlying Genetic Cause in a Cohort of Russian Patients with Familial Hypercholesterolemia Using Targeted Next Generation Sequencing","volume":"7","author":"AE Semenova","year":"2020","journal-title":"J Cardiovasc Dev Dis"},{"key":"pone.0255523.ref004","doi-asserted-by":"crossref","first-page":"1845969","DOI":"10.1155\/2020\/1845969","article-title":"The Peroxisome Proliferator-Activated Receptor \u03b3 Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting Myeloperoxidase","volume":"2020","author":"D Zhang","year":"2020","journal-title":"Cardiol Res Pract"},{"key":"pone.0255523.ref005","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/bph.13704","article-title":"Effect of hypercholesterolaemia on myocardial function, ischaemia\u2013reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning","volume":"174","author":"I Andreadou","year":"2017","journal-title":"Br J Pharmacol"},{"key":"pone.0255523.ref006","volume-title":"The role of lipids and lipoproteins in atherosclerosis","author":"MF Linton","year":"2019"},{"key":"pone.0255523.ref007","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11239-016-1364-1","article-title":"PCSK9 inhibitors in the prevention of cardiovascular disease","volume":"42","author":"J Latimer","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"pone.0255523.ref008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: Its role in LDL metabolism","volume":"32","author":"JD Horton","year":"2007","journal-title":"Trends Biochem Sci"},{"issue":"6","key":"pone.0255523.ref009","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"HJ Kwon","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"pone.0255523.ref010","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: A convertase that coordinates LDL catabolism","volume":"50","author":"JD Horton","year":"2009","journal-title":"J Lipid Res"},{"key":"pone.0255523.ref011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pcad.2015.04.004","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy","volume":"58","author":"L Joseph","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"key":"pone.0255523.ref012","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1081\/DMR-55225","article-title":"Bioinformatics in drug development and assessment","volume":"37","author":"DS Wishart","year":"2005","journal-title":"Drug Metab Rev"},{"key":"pone.0255523.ref013","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.drudis.2018.05.041","article-title":"Bioinformatics-based tools in drug discovery: The cartography from single gene to integrative biological networks","volume":"23","author":"P Ramharack","year":"2018","journal-title":"Drug Discov Today"},{"key":"pone.0255523.ref014","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/ijerph16060923","article-title":"A molecular docking approach to evaluate the pharmacological properties of natural and synthetic treatment candidates for use against hypertension","volume":"16","author":"SA Attique","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"pone.0255523.ref015","doi-asserted-by":"crossref","first-page":"D437","DOI":"10.1093\/nar\/gkaa1038","article-title":"RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences","volume":"49","author":"SK Burley","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"pone.0255523.ref016","doi-asserted-by":"crossref","first-page":"43054","DOI":"10.1074\/jbc.M111.273474","article-title":"Novel domain interaction regulates secretion of proprotein convertase subtilisin\/kexin type 9 (PCSK9) protein","volume":"286","author":"F Du","year":"2011","journal-title":"J Biol Chem"},{"key":"pone.0255523.ref017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chembiol.2019.10.002","article-title":"From screening to targeted degradation: strategies for the discovery and optimization of small molecule ligands for PCSK9","volume":"27","author":"WL Petrilli","year":"2020","journal-title":"Cell Chem Biol"},{"key":"pone.0255523.ref018","first-page":"2778","article-title":"LigPlot+: multiple ligand\u2013protein interaction diagrams for drug discovery","volume":"51","author":"RA Laskowski","year":"2011","journal-title":"ACS Publications"},{"issue":"5","key":"pone.0255523.ref019","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein\u2013ligand docking and virtual drug screening with the AutoDock suite","volume":"11","author":"S Forli","year":"2016","journal-title":"Nat Protoc"},{"key":"pone.0255523.ref020","doi-asserted-by":"crossref","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","article-title":"PubChem in 2021: new data content and improved web interfaces","volume":"49","author":"S Kim","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"pone.0255523.ref021","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"O Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"pone.0255523.ref022","doi-asserted-by":"crossref","first-page":"W223","DOI":"10.1093\/nar\/gkn187","article-title":"PharmaGist: a webserver for ligand-based pharmacophore detection","volume":"36","author":"D Schneidman-Duhovny","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"pone.0255523.ref023","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1089\/cmb.2007.0130","article-title":"Deterministic pharmacophore detection via multiple flexible alignment of drug-like molecules","volume":"15","author":"D Schneidman-Duhovny","year":"2008","journal-title":"J Comput Biol"},{"key":"pone.0255523.ref024","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10822-016-9900-9","article-title":"1001 Ways to run AutoDock Vina for virtual screening","volume":"30","author":"MM Jaghoori","year":"2016","journal-title":"J Comput Aided Mol Des"},{"key":"pone.0255523.ref025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1517\/17460441.1.3.261","article-title":"Pharmacophore modelling: applications in drug discovery","volume":"1","author":"T Langer","year":"2006","journal-title":"Expert Opin Drug Discov"},{"key":"pone.0255523.ref026","doi-asserted-by":"crossref","first-page":"W409","DOI":"10.1093\/nar\/gks378","article-title":"ZINCPharmer: Pharmacophore search of the ZINC database","volume":"40","author":"DR Koes","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"pone.0255523.ref027","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: An open chemical toolbox","volume":"3","author":"NM O\u2019Boyle","year":"2011","journal-title":"J Cheminform"},{"key":"pone.0255523.ref028","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15\u2013ligand discovery for everyone","volume":"55","author":"T Sterling","year":"2015","journal-title":"J Chem Inf Model"},{"key":"pone.0255523.ref029","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"A Daina","year":"2017","journal-title":"Sci Rep"},{"key":"pone.0255523.ref030","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/bioinformatics\/bty707","article-title":"admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties","volume":"35","author":"H Yang","year":"2019","journal-title":"Bioinformatics"},{"key":"pone.0255523.ref031","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"MJ Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"pone.0255523.ref032","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"A Waterhouse","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"pone.0255523.ref033","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1093\/bioinformatics\/bth191","article-title":"UniProt archive","volume":"20","author":"R Leinonen","year":"2004","journal-title":"Bioinformatics"},{"key":"pone.0255523.ref034","doi-asserted-by":"crossref","first-page":"D204","DOI":"10.1093\/nar\/gku989","article-title":"UniProt: a hub for protein information","volume":"43","author":"U Consortium","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"pone.0255523.ref035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1758-2946-4-17","article-title":"Avogadro: an advanced semantic chemical editor, visualization, and analysis platform","volume":"4","author":"MD Hanwell","year":"2012","journal-title":"J Cheminform"},{"key":"pone.0255523.ref036","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: Visual molecular dynamics","volume":"14","author":"W Humphrey","year":"1996","journal-title":"J Mol Graph"},{"key":"pone.0255523.ref037","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejmech.2018.11.011","article-title":"Small molecules as inhibitors of PCSK9: Current status and future challenges","volume":"162","author":"S Xu","year":"2019","journal-title":"Eur J Med Chem"},{"key":"pone.0255523.ref038","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00464391","article-title":"Oral antipyretic therapy","volume":"121","author":"S Simil\u00e4","year":"1975","journal-title":"Eur J Pediatr"},{"key":"pone.0255523.ref039","first-page":"366","article-title":"In vitro ADME studies of TUG-891, a GPR-120 inhibitor using SWISS ADME predictor","volume":"9","author":"S Mishra","year":"2019","journal-title":"J Drug Deliv Ther"},{"key":"pone.0255523.ref040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: a new era of lipid lowering therapy","volume":"9","author":"R Chaudhary","year":"2017","journal-title":"World J Cardiol"},{"key":"pone.0255523.ref041","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00041433-200104000-00008","article-title":"Very-low-density lipoprotein assembly and secretion","volume":"12","author":"GS Shelness","year":"2001","journal-title":"Current Opinion in Lipidology"},{"key":"pone.0255523.ref042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.cb.01.110185.000245","article-title":"Receptor-mediated endocytosis: concepts emerging from the LDL receptor system","volume":"1","author":"JL Goldstein","year":"1985","journal-title":"Annu Rev Cell Biol"},{"key":"pone.0255523.ref043","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells","volume":"282","author":"MC McNutt","year":"2007","journal-title":"J Biol Chem"},{"key":"pone.0255523.ref044","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/eurheartj\/16.suppl_K.49","article-title":"Potential role of angiotensin converting enzyme inhibitors in the treatment of atherosclerosis","volume":"16","author":"B Pitt","year":"1995","journal-title":"Eur Heart J"},{"key":"pone.0255523.ref045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10557-010-6244-x","article-title":"Secondary prevention of CAD with ACE inhibitors: A struggle between life and death of the endothelium","volume":"24","author":"R Ferrari","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"key":"pone.0255523.ref046","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00129784-200101050-00001","article-title":"Antiatherosclerotic effects of ACE inhibitors","volume":"1","author":"E Lonn","year":"2001","journal-title":"Am J Cardiovasc Drugs"},{"key":"pone.0255523.ref047","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/13880209.2016.1230635","article-title":"Haematopoietic effects of Angelica sinensis root cap polysaccharides against lisinopril-induced anaemia in albino rats","volume":"55","author":"F Younas","year":"2017","journal-title":"Pharm Biol"},{"key":"pone.0255523.ref048","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2125.1994.tb04240.x","article-title":"Effects of ACE inhibitors on oxidation of human low density lipoprotein","volume":"37","author":"EG Godfrey","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0255523.ref049","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00228-011-1029-0","article-title":"Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients","volume":"67","author":"F Cacciatore","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"pone.0255523.ref050","doi-asserted-by":"crossref","first-page":"1470320316647239","DOI":"10.1177\/1470320316647239","article-title":"Quinapril decreases antifibrinolytic and prooxidative potential of propofol in arterial thrombosis in hypertensive rats","volume":"17","author":"M Wojewodzka-Zelezniakowicz","year":"2016","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"pone.0255523.ref051","first-page":"514","article-title":"Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease","volume":"60","author":"R Krysiak","year":"2008","journal-title":"Pharmacol Reports"},{"key":"pone.0255523.ref052","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"K Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"pone.0255523.ref053","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/clc.4960160407","article-title":"Fosinopril monotherapy: Relationship between blood pressure reduction and time of administration","volume":"16","author":"NF Ford","year":"1993","journal-title":"Clin Cardiol"},{"key":"pone.0255523.ref054","doi-asserted-by":"crossref","first-page":"300S","DOI":"10.1093\/ajh\/1.3.300S","article-title":"Efficacy and safety of cilazapril, a new angiotensin-converting enzyme inhibitor","volume":"1","author":"RC Goldszer","year":"1988","journal-title":"Am J Hypertens"},{"key":"pone.0255523.ref055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00129784-200303050-00006","article-title":"ACE Inhibition with Moexipril","volume":"3","author":"A Pines","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"pone.0255523.ref056","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1039\/C8MD00472B","article-title":"ADMET-score\u2013a comprehensive scoring function for evaluation of chemical drug-likeness","volume":"10","author":"L Guan","year":"2018","journal-title":"Medchemcomm"},{"key":"pone.0255523.ref057","first-page":"147","article-title":"Bioavailability prediction of phytochemicals present in Calotropis procera (Aiton) R. Br. by using Swiss-ADME tool","volume":"131","author":"P Tripathi","year":"2019","journal-title":"World Sci News"},{"key":"pone.0255523.ref058","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4155\/fmc-2018-0294","article-title":"Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy","volume":"11","author":"A Lavecchia","year":"2019","journal-title":"Future Med Chem"},{"key":"pone.0255523.ref059","first-page":"1939","article-title":"Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction","volume":"41","author":"Q Wan","year":"2018","journal-title":"Int J Mol Med"},{"issue":"Forthcoming","key":"pone.0255523.ref060","author":"K Wu","year":"2020","journal-title":"Network Pharmacological Analysis of Huanglian Jiedu Decoction for Anti-Atherosclerosis"},{"key":"pone.0255523.ref061","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12906-016-1165-2","article-title":"Role of hesperetin in LDL-receptor expression in hepatoma HepG2 cells","volume":"16","author":"NA Bawazeer","year":"2016","journal-title":"BMC Complement Altern Med"},{"key":"pone.0255523.ref062","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"American College of Cardiology Foundation","year":"2013","journal-title":"J Amer Coll Cardiol"},{"key":"pone.0255523.ref063","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1194\/jlr.M300203-JLR200","article-title":"Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice","volume":"44","author":"KN Maxwell","year":"2003","journal-title":"J Lipid Res"},{"key":"pone.0255523.ref064","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: increasing saturation as an approach to improving clinical success","volume":"52","author":"F Lovering","year":"2009","journal-title":"J Med Chem"},{"key":"pone.0255523.ref065","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.drudis.2020.07.017","article-title":"Fsp3: A new parameter for drug-likeness","volume":"25","author":"W Wei","year":"2020","journal-title":"Drug Discov Today"},{"key":"pone.0255523.ref066","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijpharm.2009.01.026","article-title":"An interesting relationship between drug absorption and melting point","volume":"373","author":"KA Chu","year":"2009","journal-title":"Int J Pharm"},{"key":"pone.0255523.ref067","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1021\/je800078j","article-title":"Solubility of hesperetin in various solvents from (288.2 to 323.2) K","volume":"53","author":"L Liu","year":"2008","journal-title":"J Chem Eng Data"},{"key":"pone.0255523.ref068","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/sj.ejcn.1602543","article-title":"Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects","volume":"61","author":"FI Kanaze","year":"2007","journal-title":"Eur J Clin Nutr"},{"key":"pone.0255523.ref069","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1631\/jzus.B1800346","article-title":"Enhanced water solubility, antioxidant activity, and oral absorption of hesperetin by D-\u03b1-tocopheryl polyethylene glycol 1000 succinate and phosphatidylcholine","volume":"20","author":"S-F Gu","year":"2019","journal-title":"J Zhejiang Univ Sci B"},{"key":"pone.0255523.ref070","volume-title":"Small animal clinical pharmacology","author":"JE Maddison","year":"2008","edition":"2"},{"key":"pone.0255523.ref071","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/pro.3289","article-title":"PDBsum: Structural summaries of PDB entries","volume":"27","author":"RA Laskowski","year":"2018","journal-title":"Protein Sci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T23:33:01Z","timestamp":1699313581000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255523"}},"subtitle":[],"editor":[{"given":"Emilio","family":"Gallicchio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":71,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0255523","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]}}}